Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2010

01-03-2010 | Original Article

Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease

Authors: Francisco J. Diaz-Corrales, Salome Sanz-Viedma, David Garcia-Solis, Teresa Escobar-Delgado, Pablo Mir

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2010

Login to get access

Abstract

Purpose

To determine clinical predictors and accuracy of 123I-FP-CIT SPECT imaging in the differentiation of drug-induced parkinsonism (DIP) and Parkinson’s disease (PD).

Methods

Several clinical features and 123I-FP-CIT SPECT images in 32 patients with DIP, 25 patients with PD unmasked by antidopaminergic drugs (PDu) and 22 patients with PD without a previous history of antidopaminergic treatment (PDc) were retrospectively evaluated.

Results

DIP and PD shared all clinical features except symmetry of parkinsonian signs which was more frequently observed in patients with DIP (46.9%) than in patients with PDu (16.0%, p<0.05) or PDc (4.5%, p<0.01). Qualitatively 123I-FP-CIT SPECT images were normal in 29 patients with DIP (90.6%) and abnormal in all patients with PD, and this imaging technique showed high levels of accuracy.

Conclusion

DIP and PD are difficult to differentiate based on clinical signs. The precision of clinical diagnosis could be reliably enhanced by 123I-FP-CIT SPECT imaging.
Literature
1.
Alvarez MV, Evidente VG. Understanding drug-induced parkinsonism. Separating pearls from oysters. Neurology 2008;70:e32–4.CrossRefPubMed
2.
Rao SS, Hofmann LA, Shakil A. Parkinson's disease: diagnosis and treatment. Am Fam Physician 2006;74:2046–54.PubMed
3.
Hirose G. Drug induced parkinsonism: a review. J Neurol 2006;253(Suppl 3):22–24.
4.
5.
Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord 2006;21:510–4.CrossRefPubMed
6.
Tolosa E, Coelho M, Gallardo M. DAT Imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;18(Suppl 7):S28–33.CrossRefPubMed
7.
Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 2007;22:1229–38.CrossRefPubMed
8.
Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415–23.CrossRefPubMed
9.
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease. Arch Neurol 1999;56:33–9.CrossRefPubMed
10.
Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503–10.CrossRefPubMed
11.
Marti Masso JF, Poza JJ. Parkinsonismo inducido o agravado por fármacos: características clínicas y evolución histórica de los fármacos implicados. Neurologia 1996;11:10–5.PubMed
12.
Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2007;23:401–4.CrossRef
13.
Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054–60.PubMed
14.
Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850–4.CrossRefPubMed
15.
Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, et al. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 2001;108:1299–308.CrossRefPubMed
16.
Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 2004;45:1688–93.PubMed
17.
Sayed IS, Zakaria A, Nik N. Comparison of Chang’s with Sorenson’s attenuation correction method by varying linear attenuation coefficient values in Tc-99m SPECT imaging. In: Gao X, et al., editors. Medical imaging and informatics. Berlin: Springer-Verlag; 2008. p. 216–22.CrossRef
18.
Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266–72.CrossRefPubMed
19.
Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175–82.CrossRefPubMed
20.
Ottaviani S, Tinazzi M, Pasquin I, Nothdurfter W, Tomelleri G, Fincati E, et al. Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease. Neurol Sci 2006;27:397–401.CrossRefPubMed
21.
Benamer HTS, Patterson J, Wyper DJ, Hadley DM, Macphee GJA, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692–8.CrossRefPubMed
22.
Seibyl JP, Marek KL, Quilan D. Decreased single-photon emission computed tomography [123I]beta-CIT striatal uptake correlated with symptom severity in Parkinson’s disease. Ann Neurol 1995;38:589–5.CrossRefPubMed
23.
Di Rocco A, Brannan T, Prikhojan A, Yahr MD. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 1998;105:247–51.CrossRefPubMed
24.
Leo RJ. Movement disorders associated with serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449–54.PubMed
25.
Pina Latorre MA, Modrego PJ, Rodilla F, Catalán C, Calvo M. Parkinsonism and Parkinson's disease associated with long-term administration of sertraline. J Clin Pharm Ther 2001;26:111–2.CrossRefPubMed
Metadata
Title
Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease
Authors
Francisco J. Diaz-Corrales
Salome Sanz-Viedma
David Garcia-Solis
Teresa Escobar-Delgado
Pablo Mir
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1289-4

Other articles of this Issue 3/2010

European Journal of Nuclear Medicine and Molecular Imaging 3/2010 Go to the issue

Guidelines

Routine quality control recommendations for nuclear medicine instrumentation

Original Article

Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys

Original Article

Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma

Image of the Month

Active inflammation in 18F-methylcholine PET/CT

Original Article

Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism

Short Communication

Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease